Theodore Karrison to Quinolines
This is a "connection" page, showing publications Theodore Karrison has written about Quinolines.
Connection Strength
0.596
-
Estimation of progression-free survival in the randomized discontinuation trial design. J Clin Oncol. 2013 Feb 20; 31(6):814.
Score: 0.423
-
A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Cancer. 2020 05 15; 126(10):2146-2152.
Score: 0.173